Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.

  title={Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.},
  author={Lorenz M Jost and Hans-Peter Gschwind and Tarja Jalava and Yongyu Wang and Clemens Guenther and Claire Souppart and Antje Rottmann and Karsten Denner and Felix Waldmeier and Gerhard Gross and Eric Masson and Dirk Laurent},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  volume={34 11},
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors. Disposition and biotransformation of vatalanib were studied in an open-label, single-center study in patients with advanced cancer. Seven patients were given a single oral (14)C-radiolabeled dose of 1,000 mg of vatalanib administered at steady state, obtained after 14 consecutive daily oral… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 22 extracted citations


Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…